Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death Ligand 1”

281 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 281 results

Large-scale testing (Phase 3)Study completedNCT02494583
What this trial is testing

Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

Who this might be right for
Gastric Adenocarcinoma
Merck Sharp & Dohme LLC 763
Not applicableUnknownNCT05964595
What this trial is testing

Temporal Diffusion Spectroscopy MRI in Predicting the CPS of PD-L1 Expression and the Efficacy of Neoadjuvant Therapy

Who this might be right for
Head and Neck Squamous Cell CarcinomaMagnetic Resonance ImagingNeoadjuvant Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 136
Early research (Phase 1)Study completedNCT05017012
What this trial is testing

Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)

Who this might be right for
Advanced or Metastatic Solid Tumors
Merck Sharp & Dohme LLC 142
Testing effectiveness (Phase 2)Active Not RecruitingNCT06483334
What this trial is testing

Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Who this might be right for
Metastatic Urothelial CarcinomaLocally Advanced Urothelial Carcinoma
Merck Sharp & Dohme LLC 38
Large-scale testing (Phase 3)Study completedNCT02256436
What this trial is testing

Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

Who this might be right for
Urothelial Cancer
Merck Sharp & Dohme LLC 542
Testing effectiveness (Phase 2)Study completedNCT03516981
What this trial is testing

Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC 245
Testing effectiveness (Phase 2)Looking for participantsNCT07111520
What this trial is testing

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
BioNTech SE 880
Large-scale testing (Phase 3)Study completedNCT03875092
What this trial is testing

Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 125
Not applicableActive Not RecruitingNCT07024862
What this trial is testing

Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

Who this might be right for
Metastatic Non-small Cell Lung Cancer
Bristol-Myers Squibb 100
Testing effectiveness (Phase 2)UnknownNCT05281003
What this trial is testing

Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)

Who this might be right for
Esophageal Squamous Cell Carcinoma
Fudan University 128
Not applicableLooking for participantsNCT06772454
What this trial is testing

To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD)

Who this might be right for
Lung Cancer Squamous CellCOPD
Guangzhou Institute of Respiratory Disease 60
Large-scale testing (Phase 3)Looking for participantsNCT06712355
What this trial is testing

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Who this might be right for
Extensive-stage Small-cell Lung Cancer
BioNTech SE 621
Large-scale testing (Phase 3)Active Not RecruitingNCT06472076
What this trial is testing

Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 88
Very early researchLooking for participantsNCT06305962
What this trial is testing

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

Who this might be right for
PDL1 Gene MutationNon Small Cell Lung CancerSmall Cell Lung Cancer ( SCLC )+6 more
Radiopharm Theranostics, Ltd 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04626518
What this trial is testing

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 370
Large-scale testing (Phase 3)UnknownNCT04203485
What this trial is testing

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
PD-L1 Positive Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 762
Large-scale testing (Phase 3)Active Not RecruitingNCT04895358
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 342
Testing effectiveness (Phase 2)Looking for participantsNCT06961006
What this trial is testing

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

Who this might be right for
Malignant Melanoma
Merck Sharp & Dohme LLC 160
Testing effectiveness (Phase 2)Looking for participantsNCT06918132
What this trial is testing

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

Who this might be right for
Lung Non-Small Cell CarcinomaStage IB Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8+2 more
Mayo Clinic 60
Testing effectiveness (Phase 2)Ended earlyNCT04152863
What this trial is testing

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Who this might be right for
Advanced/Metastatic Melanoma
Merck Sharp & Dohme LLC 85
Next Page